Wall Street wags say a bill to force insurers or PBMs to sell pharmacies has low odds

Taking stock of the drug industry, from the lab to the medicine chest

December 11, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Kevin Dietsch/AP STAT+ | Wall Street wags say a bill to force insurers or PBMs to sell pharmacies has low odds At issue is concern the big PBMs — controlled by CVS Health, Cigna, and UnitedHealth Group — favor their own mail order or retail pharmacies. By Ed Silverman STAT+ | Eli Lilly strikes Zepbound deal with Ro, amid questions about future of compounded GLP-1s Under the new agreement, patients will be able to order vials of Zepbound through Ro's app. By Elaine Chen and Katie Palmer STAT+ | With promising early data in triple negative breast cancer, a new bispecific heats up Researchers working with BioNTech found a bispecific was effective in treating triple negative breast cancer patients in small trial. By Angus Chen Adobe STAT+ | Gene-editing field sees another merger, this time between Chroma Medicine and Nvelop Therapeutics In industry parlance, the deal joins a "delivery" company with a "cargo" company — fusing the two key pieces needed to build a genetic medicine. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser